Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For LOV111818/OM6X - Subjects were included in the study if they had met all relevant inclusion/exclusion criteria prior to and throughout the double-blind Study LOV111858/OM6 and completed Study LOV111858/OM6 to Week 8.~FYI - entry criteria for LOV111818/OM6 (double-blind study)~Inclusion Criteria:~* Men and women ages 18-79 years, inclusive~* Current therapy with a statin drug~* Triglyceride levels between 200 and 499 mg/dL~* Normally active and in good health on the basis of medical history, brief physical examination, electrocardiogram, and routine laboratory tests~* Provide written informed consent and authorization for protected health information disclosure~Exclusion Criteria:~* Sensitivity to statin drugs or omega-3 fatty acids~* Lipoprotein lipase impairment or apo C-2 deficiency or type III hyperlipidemia~* Unexplained muscle pain or weakness~* History of pancreatitis~* Recent history of certain heart, kidney, liver, lung, or gastrointestinal diseases, or cancer (except non-melanoma skin cancer)~* Poorly controlled diabetes, or receiving insulin therapy~* Pregnant or lactating females. Women of childbearing potential who are not using a medically approved method of contraception.~* Use of certain types of hormones, anticonvulsant drugs, immunologic drugs, antibiotic, antifungal and antiviral drugs, and cardiac drugs~* Use of warfarin (Coumadin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Simvastatin + Lovaza® (Non-switchers) (Type: EXPERIMENTAL): Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + Lovaza® in the double-blind trial, hence in this open-label extension, they are termed Non-switchers
- Simvastatin + Lovaza® (Switchers) (Type: EXPERIMENTAL): Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + placebo in the double-blind trial, hence in this open-label extension, they are termed Switchers

Based on this trial design, predict the completion outcome and termination type (if applicable).